Cas no 110078-46-1 (PLERIXAFOR)

Plerixafor is a small-molecule CXCR4 chemokine receptor antagonist used primarily in hematopoietic stem cell transplantation. Its key advantage lies in its ability to mobilize stem cells from the bone marrow into peripheral blood, facilitating collection for autologous transplants in patients with non-Hodgkin's lymphoma or multiple myeloma. The compound exhibits high selectivity for CXCR4, disrupting the CXCL12-CXCR4 axis and promoting stem cell release. Clinically, plerixafor demonstrates a rapid onset of action and is often administered in combination with granulocyte-colony stimulating factor (G-CSF) to enhance stem cell yield. Its well-characterized pharmacokinetic profile and predictable mobilization kinetics contribute to its utility in transplant protocols.
PLERIXAFOR structure
PLERIXAFOR structure
Product Name:PLERIXAFOR
CAS No:110078-46-1
MF:C28H54N8
MW:502.781965732574
MDL:MFCD05662218
CID:62796
PubChem ID:65015
Update Time:2025-06-13

PLERIXAFOR Chemical and Physical Properties

Names and Identifiers

    • PLERIXAFOR
    • MOZOBIL PLERIXAFOR
    • 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
    • 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-
    • Mozobil
    • Sdz sid 791
    • Unii-S915p5499n
    • 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
    • Plerixafor(AMD3100)
    • 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
    • AMD 3100
    • &nbsp
    • AMD310
    • AMD-3100
    • JM 3100
    • JM-3100
    • AMD3100 (Plerixafor)
    • Plerixafor (AMD3100)
    • 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene octahydrochloride;Plerixafor octahydrochloride
    • 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
    • 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]
    • 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane
    • 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA)
    • HY-10046
    • YIQPUIGJQJDJOS-UHFFFAOYSA-N
    • DB06809
    • 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
    • Plerixafor [USAN:INN:BAN]
    • Plerixafor [USAN]
    • CS-0451
    • PLERIXAFOR [MI]
    • AB01566900_01
    • BRD-K33240821-367-01-8
    • SR-01000941593
    • AS-42504
    • 1,1'-(1,4-Phenylenebismethylene)bis(1,4,8,11-tetraazacyclotetradecane)
    • Plerixafor hydrochloride
    • J-503718
    • 1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)
    • PLERIXAFOR [WHO-DD]
    • Q905835
    • DTXSID70869520
    • FT-0660392
    • CHEMBL18442
    • PLERIXAFOR [JAN]
    • 1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE
    • 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
    • A809618
    • 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
    • NCGC00165722-02
    • JM 2987
    • EN300-187119
    • plerixaforum
    • JKL 169
    • CCG-269710
    • PLERIXAFOR (MART.)
    • 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA)
    • 1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane)
    • PLERIXAFOR [ORANGE BOOK]
    • NSC-761388
    • bicyclam JM-2987
    • PLERIXAFOR [MART.]
    • NSC761388
    • EX-A1762
    • S915P5499N
    • CHEBI:125354
    • SR-01000941593-1
    • s8030
    • SID791
    • AC-26837
    • Z1889837352
    • L03AX16
    • AMD3100
    • PLERIXAFOR [INN]
    • GTPL844
    • SY042073
    • JM3100
    • NSC754363
    • BCPP000104
    • Plerixafor (JAN/USAN/INN)
    • A25446
    • NSC-754363
    • D08971
    • DTXCID60817494
    • GNA & AMD-3100
    • 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane
    • Mozobil (TN)
    • NCGC00165722-01
    • P2678
    • 1-((4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl)methyl)-1,4,8,11-tetrazacyclotetradecane
    • L000104
    • SCHEMBL19038
    • AMD-3100 (CXCR4)
    • 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane
    • HHA & AMD-3100
    • PLERIXAFOR [EMA EPAR]
    • AKOS005266706
    • NCGC00165722-03
    • 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane
    • BDBM50035696
    • FT-0673966
    • MFCD05662218
    • 110078-46-1
    • 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
    • 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O)
    • NS00004748
    • PLERIXAFOR [VANDF]
    • BCP02337
    • 1,1'-(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane
    • 1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane)
    • VH6
    • BRD-K33240821-400-02-5
    • Plerixafor 8HCl
    • BRD-K33240821-001-03-9
    • BRD-K33240821-001-06-2
    • Plerixafor (AMD3100)?
    • BRD-K33240821-001-05-4
    • MDL： MFCD05662218
    • Inchi： 1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
    • InChI Key： YIQPUIGJQJDJOS-UHFFFAOYSA-N
    • SMILES： N1(CCNCCCNCCNCCC1)CC1C=CC(=CC=1)CN1CCNCCCNCCNCCC1

Computed Properties

  • Exact Mass: 502.44700
  • Monoisotopic Mass: 1141.856
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 6
  • Hydrogen Bond Acceptor Count: 8
  • Heavy Atom Count: 36
  • Rotatable Bond Count: 4
  • Complexity: 456
  • Covalently-Bonded Unit Count: 9
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 78.7A^2
  • XLogP3: 0

Experimental Properties

  • Color/Form: White to off white solid powder
  • Density: 0.962
  • Melting Point: 122-125°C
  • Boiling Point: 657.5°C at 760 mmHg
  • Flash Point: 361.8±26.2 °C
  • PSA: 78.66000
  • LogP: 2.26440
  • Vapor Pressure: 0.0±2.0 mmHg at 25°C

PLERIXAFOR Security Information

PLERIXAFOR Customs Data

  • HS CODE：2933990090
  • Customs Data：

    China Customs Code:

    2933990090

    Overview:

    2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

    Summary:

    2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

PLERIXAFOR Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
A966133-5mg
amd 3100
 110078-46-1
5mg
 $ 90.00 2022-06-07
TRC
A966133-10mg
amd 3100
 110078-46-1
10mg
 $ 125.00 2022-06-07
TRC
A966133-25mg
amd 3100
 110078-46-1
25mg
 $ 285.00 2022-06-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
097330-1g
PLERIXAFOR
 110078-46-1 95+%
1g
 9558.0CNY 2021-08-03
SHANG HAI XIAN DING Biotechnology Co., Ltd.
097330-250mg
PLERIXAFOR
 110078-46-1 95+%
250mg
 4307.0CNY 2021-08-03
SHANG HAI XIAN DING Biotechnology Co., Ltd.
A-IX688-100mg
PLERIXAFOR
 110078-46-1 99%
100mg
 667.0CNY 2021-08-03
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
P2678-250MG
Plerixafor
 110078-46-1 >98.0%(GC)
250mg
 ￥1490.00 2024-04-18
TRC
P580500-5mg
Plerixafor
 110078-46-1
5mg
 $92.00 2023-05-17
TRC
P580500-10mg
Plerixafor
 110078-46-1
10mg
 $127.00 2023-05-17
TRC
P580500-25mg
Plerixafor
 110078-46-1
25mg
 $ 292.00 2023-09-06

PLERIXAFOR Related Literature

Related Categories

Additional information on PLERIXAFOR

PLERIXAFOR (CAS No. 110078-46-1): A Comprehensive Overview

PLERIXAFOR (CAS No. 110078-46-1), also known as Mozobil, is a small molecule chemokine receptor antagonist that has gained significant attention in the field of hematopoietic stem cell mobilization. This compound is a potent and selective inhibitor of the CXCR4 receptor, which plays a crucial role in the retention of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. By blocking the interaction between CXCR4 and its ligand, stromal cell-derived factor-1 (SDF-1), PLERIXAFOR facilitates the mobilization of HSPCs into the peripheral blood, making it an essential tool in autologous stem cell transplantation (ASCT) and other therapeutic applications.

The discovery and development of PLERIXAFOR have been driven by the need for more effective and less invasive methods to mobilize HSPCs. Traditional methods, such as granulocyte colony-stimulating factor (G-CSF) alone, often fail to achieve sufficient mobilization in a significant proportion of patients. PLERIXAFOR, when used in combination with G-CSF, has shown superior efficacy in mobilizing HSPCs, leading to improved patient outcomes and reduced treatment times.

Clinical trials have demonstrated the safety and efficacy of PLERIXAFOR. In a pivotal Phase III trial, patients treated with a combination of PLERIXAFOR and G-CSF achieved significantly higher rates of successful stem cell collection compared to those treated with G-CSF alone. The most common adverse effects observed were mild to moderate and included nausea, diarrhea, headache, and injection site reactions. These findings have led to the approval of PLERIXAFOR by regulatory agencies such as the FDA and EMA for use in ASCT.

Beyond its primary application in ASCT, PLERIXAFOR has shown promise in other areas of medicine. Recent research has explored its potential in enhancing the efficacy of cancer immunotherapies by mobilizing immune cells to tumor sites. Studies have also investigated its use in regenerative medicine, where it may help promote tissue repair and regeneration by facilitating the migration of stem cells to damaged tissues.

The mechanism of action of PLERIXAFOR is well understood. It binds to the CXCR4 receptor on HSPCs and other cell types, preventing the interaction with SDF-1. This disruption leads to the release of HSPCs from their niches in the bone marrow into the peripheral blood. The rapid onset of action and short half-life of PLERIXAFOR make it particularly suitable for clinical use, as it allows for precise control over the timing and extent of stem cell mobilization.

In addition to its clinical applications, PLERIXAFOR has been studied extensively at the molecular level. Research has elucidated its binding affinity for CXCR4 and its effects on downstream signaling pathways. These studies have provided valuable insights into the role of CXCR4 in various physiological processes and have opened new avenues for therapeutic intervention.

The development of PLERIXAFOR has also spurred interest in other CXCR4 antagonists. Several compounds are currently under investigation for their potential use in stem cell mobilization and other therapeutic applications. These include small molecules, peptides, and antibodies that target different aspects of CXCR4 function.

In conclusion, PLERIXAFOR (CAS No. 110078-46-1) represents a significant advancement in the field of hematopoietic stem cell mobilization. Its unique mechanism of action, safety profile, and clinical efficacy have established it as a valuable tool in ASCT and other therapeutic settings. Ongoing research continues to explore new applications for this compound, further solidifying its importance in modern medicine.

110078-46-1 (PLERIXAFOR) Related Products

Recommended suppliers
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd
鉅瀾化工科技(青島)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
鉅瀾化工科技(青島)有限公司
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd